Condition 1: Chronic kidney disease, stage 1. Condition 2: Chronic kidney disease, stage 2. Condition 3: Chronic kidney disease, stage 3. Condition 4: Chronic kidney disease, stage 4. Kidney damage with normal or increased GFR (> 90 mL/min) Kidney damage with mild decreased GFR (60-89 mL/min) Kidney damage with moderately decreased GFR (30-59 mL/min) Kidney damage with severely decreased GFR (15-29 mL/min)
Conditions
Interventions
Intervention 1: The intervention group in addition to routine treatment will receive camel milk a daily dose of 400 ml for three months. Intervention 2: The control group will receive the routine Trea
Treatment - Other
Treatment - Drugs
The intervention group in addition to routine treatment will receive camel milk a daily dose of 400 ml for three months.
The control group will receive the routine Treatments
Sponsors
Vice Chancellor for Research and Technology Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 70 Years
Inclusion criteria
Inclusion criteria: patients with chronic kidney disease; aged 15 to 70 years
Exclusion criteria
Exclusion criteria: Patients with chronic kidney disease concomitant uncontrolled diabetes(Hb A1c less than 9 and fasting blood sugar greater than 130) Patients with uncontrolled hypertension(systolic blood pressure of 160 mm Hg and higher and diastolic blood pressure of 100 mm Hg and higher) cancer patients patients with urinary obstruction the fifth stage of chronic kidney disease patients with acute infection and feverish patients who are taking nephrotoxic drugs patients with heart failure liver failure poly cystic kidney pregnancy patients who had kidney transplant drug addicts
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glomerular filtration rate. Timepoint: Before the intervention, the end of intervention. Method of measurement: Cockcroft gault Formula, MDRD. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hb. Timepoint: The beginning of the study, the end of the study. Method of measurement: Laboratory blood test.;Urinary albumin. Timepoint: The beginning of the study, the end of the study. Method of measurement: Evaluation of urine.;24 hour urine protein level. Timepoint: The beginning of the study, the end of the study. Method of measurement: 24 hour urine evaluation.;Serum alkaline phosphatase levels. Timepoint: The beginning of the study, the end of the study. Method of measurement: Laboratory blood test.;Serum PTH level. Timepoint: The beginning of the study, the end of the study. Method of measurement: Laboratory blood test.;Blood uric acid. Timepoint: Before the intervention, the end of intervention. Method of measurement: Laboratory blood test.;Serum calcium. Timepoint: The beginning of the study, the end of the study. Method of measurement: Laboratory blood test.;Serum sodium. Timepoint: The beginning of the study, the end of the study. Method of measurement: Laboratory blood test.;Serum potassium. Timepoint: The beginning of the study, the end of the study. Method of measurement: Laboratory blood test.;Serum CRP levels. Timepoint: The beginning of the study, The end of the study. Method of measurement: Laboratory blood test.;Blood pressure. Timepoint: The beginning of the study, the end of the study. Method of measurement: By Sphygmomanometer.;FBS. Timepoint: The beginning of the study,Middle of the study, The end of the study. Method of measurement: Laboratory blood test.;HbA1C. Timepoint: The beginning of the study, the end of the study. Method of measurement: Laboratory blood test.;Lipid profile. Timepoint: The beginning of the study, the end of the study. Method of measurement: Laboratory blood test.;Serum creatinine. Timepoint: Before the intervention, the end of intervention. Method of measurement: Evaluation of serum. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmirparviz Tavassoli
Mashhad University of Medical Sciences
Outcome results
None listed